digital ulcers

01/01/2012 - "These results suggest that bosentan is an effective treatment for refractory digital ulcers associated with SSc; however, liver function should be carefully monitored. "
01/01/2017 - "The safety and tolerability of bosentan was monitored over 52 weeks of study treatment (primary end-point), while incidence and healing of digital ulcers were also assessed up to week 16. "
09/01/2016 - "The study included 30 patients (4 males, 26 females; mean age 49.6±15.4 years; range 23 to 71 years) diagnosed with SSc and treated with bosentan for digital ulcers. "
12/01/2010 - "Double-blind randomized clinical trials are needed to evaluate the effects of bosentan on skin perfusion of SSc patients without PAH and with active digital ulcers."
04/01/2006 - "Forthcoming results from the international RAPIDS-2 study should clarify the indications for bosentan in the treatment of SSc-related digital ulcers."

09/01/2003 - "In three different studies, iloprost given for 5 days in the highest tolerated dose of 1-2 ng/kg/min provided a significant improvement of the disease measured by the number and intensity of Raynaud attacks, healing of digital ulcers, and digital perfusion. "
03/15/2007 - "g., iloprost, can be recommended as first-line treatment of ischemic digital ulcers. "
01/01/2000 - "Intravenous Iloprost is effective in the treatment of Raynaud's phenomenon secondary to scleroderma at decreasing the frequency and severity of attacks and preventing or healing digital ulcers. "
02/01/2004 - "Iloprost appears to be a safe and effective treatment for ischaemic digits and digital ulcers in children with CTD. "
09/01/2017 - "The objective of the study is to evaluate the feasibility, safety and efficacy of home infusion of iloprost with the new portable syringe pump Infonde®, for the treatment of scleroderma-related Raynaud's phenomenon and digital ulcers. "

01/01/2013 - "Endothelin receptor antagonists and scleroderma related digital ulcers."
01/01/2011 - "The purpose of this paper is to summarize the published studies and case reports evaluating the efficacy of endothelin receptor antagonists in the treatment of Raynaud's phenomenon and digital ulcers associated with systemic sclerosis."
11/24/2014 - "Endothelin receptor antagonists (ETRAs) are approved for the treatment of pulmonary hypertension and scleroderma-related digital ulcers. "
01/01/2011 - "Endothelin Receptor Antagonists for the Treatment of Raynaud's Phenomenon and Digital Ulcers in Systemic Sclerosis."
12/01/2004 - "Treatment with the endothelin receptor antagonist bosentan may be effective in preventing new digital ulcers and improving hand function in patients with SSc."

03/01/2008 - "This case demonstrates the efficacy of sildenafil in the treatment of scleroderma-associated refractory acral ulcers."
06/01/2017 - "Sildenafil, 20 mg tid, was introduced due to active digital ulcers. "
08/01/2010 - "In this pilot study, the effect of sildenafil on digital ulcer (DU) healing and related clinical symptoms was analysed. "
03/01/2008 - "[Fast and efficient healing of scleroderma-associated acral ulcers with sildenafil]."
06/01/2016 - "Efficacy of sildenafil on ischaemic digital ulcer healing in systemic sclerosis: the placebo-controlled SEDUCE study."

06/01/2009 - "Although remarkably reduced velocity was observed in SSc patients with intractable digital ulcers (72.1% reduction), it was significantly improved by lipo-prostaglandin E(1) (lipo-PGE(1)) infusion. "
12/01/1992 - "Although studies continue to demonstrate the benefit of intravenous prostaglandins in the treatment of Raynaud's phenomenon and digital ulcers in scleroderma, an initial report of oral prostaglandins was disappointing. "
08/01/2012 - "In the prevention of digital ulcers (DU), initial treatment was a CCB (73%), then adding a PDE5i, then use of a ERA, and then a prostanoid (44% agreed). "
01/01/2022 - "Iloprost (ILO), a prostaglandin analogous, is used for the treatment of SSc-related Raynaud's phenomenon and digital ulcers. "
01/01/2011 - "Prostanoids, especially iloprost, are widely used as intravenous formulas for the treatment of severe Raynaud's phenomenon (RP) and digital ulcers (DU). "

01/01/2016 - "Raynaud's phenomenon, digital ulcers, and physician global assessments improved in the majority of studies of statin treatment in SSc. "
02/01/2009 - "They observed significant reductions in the overall number of digital ulcers and in the mean number of new digital ulcers per patient in the statin group. "
09/01/2008 - "Statins: potentially useful in therapy of systemic sclerosis-related Raynaud's phenomenon and digital ulcers."
01/01/2019 - "Among clinical characteristics, anti-Scl70 antibody positivity, digital ulcers history and smoke exposure affected NIRS parameters, as well as sildenafil and statins therapy. "
11/01/2011 - "Key points include phosphodiesterase inhibitors most likely confer benefit, although clinical trials have given somewhat conflicting results, and have been short-term; a new topical, easy-to-use glyceryl trinitrate preparation has been shown to improve Raynaud's Condition Score; the endothelin-1 receptor antagonist bosentan has now been shown to reduce the number of new systemic sclerosis (SSc)-related digital ulcers in two multinational clinical trials; and although statin therapy is likely to confer benefit in SSc-related Raynaud's phenomenon, further research is required to confirm this. "

11/01/2011 - "New therapeutic approaches in patients who do not respond to more traditionally used vasodilators include phosphodiesterase inhibitors and (for those with recurrent SSc-related digital ulcers) endothelin-1 receptor antagonism. "
02/01/2012 - "Better understanding of SSc pathogenesis resulted in the development of drugs, such as prostanoids, endothelin-1 and phosphodiesterase inhibitors, for treatment of pulmonary arterial hypertension and digital ulcers. "
01/01/2020 - "Phosphodiesterase inhibitors (such as sildenafil) and endothelin receptor antagonist, bosentan, are effective for digital ulcer disease in systemic sclerosis (SSc-DU) and are endorsed in international treatment recommendations. "
11/01/2012 - "Many agents are available for the circulatory problems including Raynaud phenomenon and digital ulcers such as calcium channel blockers, ACE inhibitors and intravenous prostacyclin derivatives, as well as endothelin receptor blockers and phosphodiesterase inhibitors. "
11/01/2011 - "Key points include phosphodiesterase inhibitors most likely confer benefit, although clinical trials have given somewhat conflicting results, and have been short-term; a new topical, easy-to-use glyceryl trinitrate preparation has been shown to improve Raynaud's Condition Score; the endothelin-1 receptor antagonist bosentan has now been shown to reduce the number of new systemic sclerosis (SSc)-related digital ulcers in two multinational clinical trials; and although statin therapy is likely to confer benefit in SSc-related Raynaud's phenomenon, further research is required to confirm this. "

12/01/2020 - "In addition, a separate patient survey was conducted by the schleroderma self-help group (Sklerodermie Selbsthilfe e. V.), which only covered the symptoms Raynaud's syndrome, digital ulcers and the use of intravenous prostacyclin derivatives. "
12/01/2016 - "Evidence for the Use of Epoprostenol to Treat Raynaud's Phenomenon With or Without Digital Ulcers."
01/01/2013 - "Prostacyclin analogues are the most effective drugs to treat sclerodermic digital ulcers, but their systemic use is limited by their frequent side effects. "
01/01/2008 - "16.6% had at least one recorded episode of digital ulcers, and 12% required at least one hospitalisation during the 18 months for treatment with intravenous prostacyclin/CGRP. "
03/21/2000 - "Trends toward greater improvement in severity of the Raynaud phenomenon and fewer new digital ulcers were seen in the epoprostenol group. "

07/06/2017 - "Efficacy of Botulinum Toxin B Injection for Raynaud's Phenomenon and Digital Ulcers in Patients with Systemic Sclerosis."
09/01/2019 - "Effects of botulinum toxin injection on systemic sclerosis-related digital ulcers."
03/01/2018 - "We recently identified the efficacy and safety of a botulinum toxin (BTX)-A/B in Raynaud's phenomenon (RP) and digital ulcers (DU) in Japanese patients with systemic sclerosis (SSc). "
03/01/2018 - "Successful treatment of Raynaud's phenomenon and digital ulcers in systemic sclerosis patients with botulinum toxin B injection: Assessment of peripheral vascular disorder by angiography and dermoscopic image of nail fold capillary."
06/22/2021 - "Among the different locoregional treatment strategies described, injections of fat-derived cells and botulinum toxin showed promising results in the reduction of pain and the number of digital ulcers. "

05/01/2021 - "The average total Botulinum toxin A dose injected was 156 U and the concentration was 50 U/ml. All patients reported an improvement in symptoms and healing of digital ulcers. "
01/01/2016 - "Management of Raynaud's digital ulcer with interdigital Botulinum toxin A injection."
01/01/2022 - "Efficacy of botulinum toxin type A injection for Raynaud's phenomenon and digital ulcers in patients with systemic sclerosis."
02/17/2014 - "[Marked effect of botulinum toxin A for severe toe digital ulcers in a patient with systemic sclerosis]."
05/01/2020 - "To evaluate the therapeutic benefit of botulinum toxin A (BTX-A) injections for digital ulcers (DU) in patients with systemic sclerosis (SSc). "

09/01/1992 - "Clinical assessments, status of digital ulcers, measures of in vivo platelet activation and detailed studies of peripheral vascular response to cold challenge, were performed at entry, at 5 days of therapy and at biweekly intervals for 10 weeks. "
06/22/2021 - "The aim of this review is to systematically assess the spectrum of published locoregional therapies for digital ulcers. "
12/01/2019 - "This review provides an overview of previous digital ulcer management and a concise summary of new peer-reviewed literature on the topic since 2015 to provide guidance to practitioners and researchers seeking well-supported and novel/off-label therapies to consider."
05/01/2017 - "The aim of this editorial is to describe the high unmet need for a standardized method of defining digital ulcers, which is a major challenge not only for treatment, but also for development of new therapies. "
01/01/2013 - "Very recently, it has been described that efficacious potentially disease modifying therapies in SSc may interfere with progression of nailfold microvascular damage, as assessed by NVC, over long term at least in presence of digital ulcers. "

01/01/2016 - "More definitive research evidence is needed in this area to determine whether or not the flexor tenotomy is a safe and effective treatment option for people with, or at risk of developing diabetic toe ulcers. "
01/01/2014 - "Percutaneous tenotomy was an effective and safe method for treating toe ulcers in neuropathic patients. "
11/01/2007 - "Toe flexor tenotomies appear to be effective and safe treatment for neuropathic toe ulcers."
05/01/2017 - "Studies were included if they had reported the effects of flexor tenotomy for healing and/or preventing diabetes-related toe ulcers. "
01/01/2022 - "Biomechanical and musculoskeletal changes after flexor tenotomy to reduce the risk of diabetic neuropathic toe ulcer recurrence."

05/01/2014 - "To avoid major amputation, we examined the safety and efficacy of therapeutic vascular angiogenesis for digital ulcers due to SSc. "
10/01/2022 - "Independent determinants of GAVE included the presence of RNAP III antibody (OR 3.46, p < 0.001), absence of Scl-70 antibody (OR 0.23, p = 0.001), presence of GIT dysmotility (OR 1.64, p = 0.004), and digital ulcers; pits; or digital amputation (OR 1.59, p = 0.014). "
11/01/2014 - "After approval by the institutional review board, a review was performed of consecutive patients who had undergone office-based distal Symes toe amputation for a non-healing tip of lesser toe ulcer from January 2007 to December 2012. "
08/01/2012 - "Nine patients (4.8%) underwent partial or total surgical digital amputation because of necrotic process; all these patients except 1 had a long history of multiple and persisting digital ulcers. "
01/01/2007 - "Complications can include digital ulcers and could, rarely, lead to amputation. "

02/01/2020 - "Successful therapy for diffuse cutaneous systemic sclerosis-induced digital ulcer treated with hyperbaric oxygen therapy."
01/01/2017 - "[Efficacy of hyperbaric oxygen therapy in the treatment of ischemic toe ulcer in a patient presenting systemic sclerosis]."
01/01/2018 - "Hyperbaric oxygen therapy can be considered as a safe and useful adjunct treatment for intractable digital ulcers in patients with Raynaud's disease."
01/01/2018 - "We present a case of Raynaud's disease with digital ulcers that was successfully treated with hyperbaric oxygen therapy. "
01/01/2018 - "Hyperbaric oxygen therapy for digital ulcers due to Raynaud's disease."

10/01/2021 - "Revision periarterial sympathectomy is effective in providing symptomatic improvement and digital ulcer healing with minimal postoperative complications.Level"
01/01/2002 - "Eight patients underwent ulnar artery revascularization combined with digital sympathectomy, and 8 experienced dramatic improvement in RP and healing of digital ulcers. "
01/01/1996 - "We have not performed upper extremity sympathectomy for nonhealing finger ulcers in more than 20 years."
09/01/1995 - "Digital sympathectomy can be an effective procedure for treating nonhealing digital ulcers in scleroderma patients after nonoperative treatment has failed. "
10/01/2018 - "Searches were performed using combinations of terms including "systemic sclerosis," "scleroderma," "management," "upper extremity," "hypercalcinosis," "Raynaud's phenomenon," "sympathectomy," and "digital ulcers." Only full-length articles written in English that discussed the management of upper extremity scleroderma were used. "